Fewer than 10% of patients who could benefit from weight-loss injections such as Wegovy are able to get them, caution the World Health Organization as it publishes its initial guidance on the medications.
Given more than one billion individuals worldwide now classified as obese, it is advocating for broader and more equitable access to these injectable treatments.
According to projections, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"Our new guidelines acknowledges that excess weight is a chronic disease that can be managed with holistic and continuous support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are key hurdles to universal availability to the treatments that can aid individuals in losing substantial weight, notes the body.
Skinny Jab Supply Crisis
Even in the present most favorable outlook, the production of such drugs could only cover about 100 million people – less than 10% of the global need, per the health organization.
The advice encourages countries and companies to increase availability, through measures including licensing agreements.
A patent on a key compound – the primary component of the drug Wegovy – is set to lapse in a number of nations in 2026.
The Way Weight-Loss Drugs Work
The injections mimick a body's own hormone to slow digestion, suppress the appetite and increase the sense of being full so individuals eat less.
Individuals commonly see weight reduction after several weeks of commencing the once-weekly jabs.
Studies indicates users may regain a significant portion a year later of halting the drug, when their normal hunger come back.
To be carrying excess weight increases your chance for developing health problems, including type 2 diabetes, heart disease, brain attack, and certain cancers.
Obesity affects people in every country and was linked to millions of deaths worldwide in 2024, as per the WHO.
